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REVIEWS AND COMMENTARY • STATEMENTS AND GUIDELINES
Interventional oncology is one of the fastest growing dis-ciplines in clinical oncology and health care in general 
(1). Its success is chiefly based on the minimally invasive 
nature of the needle-, applicator-, and catheter-based im-
age-guided procedures with lower complication rates, su-
perior toxicity profiles, and often comparable or superior 
mid- and long-term oncologic outcomes compared with 
conventional treatment modalities such as surgical resec-
tion and systemic therapy (2–7). In clinical oncology, the 
most objectively defined time-to-event end point to ad-
dress clinical benefit is overall survival. However, a pro-
liferation of pharmacologic treatments and dosing strate-
gies has led to the use of surrogate end points to measure 
interim treatment efficacy. Depending on the disease 
setting, these include disease-free, recurrence-free, and 
progression-free survival; local tumor progression-free 
survival; organ-specific progression-free survival and dis-
tant progression-free survival; time to progression; time 
to local (tumor) progression and time to organ-specific 
progression; primary and assisted technique efficacy rates; 
local tumor progression rate; and local control (8,9).
Throughout the interventional oncology literature, 
these survival terms are loosely defined and are often 
incorrectly used interchangeably. Accurate comparisons 
between studies are hampered by the heterogeneous and 
unclear reporting of oncologic outcome parameters, 
which includes variability in the interpretation and use 
of time-to-event end point terms and definitions of 
starting and ending times.
In 2014, Ahmed et al (8) updated their keystone con-
sensus report regarding the standardization of terminology 
and reporting criteria, improving the precision of com-
munications in this field. Although their article and the 
supplement to the consensus document concisely mention 
that (a) reporting of overall survival from start of ablation 
and from time of diagnosis is required for all intermediate- 
and long-term studies; (b) survival at specified time points 
and median survival times should be reported, as well as 
time to progression and progression-free survival; and 
(c) local time to progression and local (tumor) progression-
free survival should be differentiated from organ-specific 
time to progression and progression-free survival, clear def-
initions and recommendations on how to use and interpret 
these parameters were not provided. Thus, in the field of 
image-guided tumor ablation, standardization of terms is 
required to facilitate effective communication.
The purpose of this modified Delphi consensus proj-
ect was to provide standardized definitions of patient-, 
session-, and tumor-related parameters and to offer rec-
ommendations on how to uniformly collect, analyze, 
and report oncologic outcomes for patients treated with 
image-guided tumor ablation. This project is a collabo-
ration between the Society of Interventional Oncology 
and the Definition for the Assessment of Time-to-Event 
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Tumor Ablation. The board members were asked to provide us 
with a list of key opinion leaders. All potential participants in 
the evaluating committee (Table E2 [online]) were required to 
confirm that they had at least 5 years of experience in the field 
of clinical oncology research, published at least one article for a 
given cancer site, and participated in at least three clinical on-
cology trials. After having confirmed these requirements in the 
online questionnaire, all were asked if they could think of further 
participants. A total of 62 key opinion leaders from Europe (n = 
29), the United States (n = 25), and Asia (n = 8) working in 48 
centers eventually joined the evaluating committee. Data on ex-
perts’ demographics, such as year of birth, current job position, 
professional membership, country of residence, time (in years) 
working in the field of interventional oncology, and familiarity 
with oncologic outcomes metrics, were collected.
Literature Review and Questionnaire Construction
A PubMed literature search resulted in a list of short-, mid-, 
and long-term oncologic outcome measures and time-to-
event end points (Appendix E1 [online]). This list was used 
by the coordinating committee to generate the first question-
naire. The formal consensus method involved the following 
steps (Figure): (a) definition of problems, literature review, 
and appointing the experts’ committees (by the coordinating 
committee); (b) development of definitions and recommen-
dations (by the coordinating committee); (c) a three-round 
rating process and evaluation of responses (by the coordinat-
ing committee plus evaluating committee); (d) presentation 
of results and final attempt to reach consensus during in-
person teleconference; and (e) creation of a final report with 
definitions plus recommendations.
Consensus Process
A modified Delphi consensus is a structured and validated 
measurement instrument used for evaluation of expert opinion 
on health and medical topics (14). It has been widely used to 
establish consensus across a range of subject areas. The Delphi 
process formalizes the degree of agreement among experts by 
using a series of surveys that are iterated with feedback until 
consensus is reached.
The guidelines were developed in four coordinating com-
mittee meetings (April 2019, June 2019, October 2019, and 
January 2020). Two rating rounds and one in-person web-based 
conference call were scheduled to develop the recommendations. 
A total of three survey rounds, or fewer if consensus was reached 
sooner, were prechosen as this enables adequate reflection on 
group responses and is considered optimal to reach consensus. 
The questionnaires were internet-based and sent by e-mail. All 
panelists received a deadline for completing the survey and were 
sent weekly reminders to encourage participation.
Before the first round, panelists agreed to review three  additional 
documents: (a) the standardization of terminology reporting cri-
teria by Ahmed et al (8), (b) the list of relevant  definitions as sug-
gested by the coordinating committee (Appendix E1 [online]), 
and (c) the key instructions for filling in the consensus document.
In round 1, statements were evaluated using a 9-point 
Likert scale (where 1 = totally disagree and 9 = totally agree) 
End Points in Cancer Trials Initiative, or DATECAN, group, 
whose final intention is to obtain harmonized consensus defi-
nitions that advance intersociety communications (9).
Study Methodology
The initial methodology was developed and previously ap-
plied in four disease-specific projects, including pancreatic 
cancer (10), sarcoma and gastrointestinal stromal tumor (11), 
breast cancer (12), and renal cell cancer (13) initiatives. Insti-
tutional review board approval was not required as this study 
does not involve human participants. This article should be 
considered a supplement to the standardization of terminol-
ogy reporting criteria recommended by Ahmed et al (8).
Coordinating Committee
The coordinating committee (Table E1 [online]) was com-
posed of Society of Interventional Oncology research com-
mittee members (M.R.M., S.N.G., M.A., M.C.S., J.C., J.P.E., 
G.  Nadolski, I.N.), one representative from the Definition for 
the Assessment of Time-to-Event End Points in Cancer Tri-
als Initiative (C.B.), one health economist (V.M.H.C.), two 
epidemiologists (V.M.H.C., B.I.L.W.), one study coordinator 
(R.S.P.), and one operations manager (T.G.). The coordinating 
committee was responsible for the methodologic protocol and 
conduct (M.R.M., R.S.P., S.N.G., M.A., M.C.S., J.C., J.P.E., 
G. Nadolski, I.N., C.B.), survey and questionnaires (all co-
ordinating committee members), data collection and analysis 
(M.R.M., R.S.P., S.N.G., M.A., C.B., V.M.H.C., B.I.L.W.), 
and guideline and manuscript preparation (all coordinating 
committee members).
Evaluating Committee
The coordinating committee reached out to at least one active 
board member of the following international scientific groups or 
organizations: Society of Interventional Oncology, Technology 
Assessment Committee of the Society of Interventional Radiol-
ogy, Standard of Practice Committee of the Cardiovascular and 
Interventional Radiological Society of Europe, Interventional 
Oncology Sans Frontières Expert Panel, and Asian Society of 
Summary
A panel of experts reached consensus on recommendations on when 
to assess oncologic outcomes per patient, per session, and per tumor; 
definitions of starting and ending times; definitions of survival time; 
and time-to-event end points.
Essentials
 n An expert panel reached consensus on (a) recommendations on 
when to assess oncologic outcomes per patient, per session, and 
per tumor; (b) definitions of starting and ending times; (c) defini-
tions of survival time; and (d) time-to-event end points.
 n Clear definitions will ensure an objective and reliable interpreta-
tion of results, allow for an accurate comparison of outcomes, 
avoid misinterpretations, and provide the necessary foundation for 
scientific reproducibility among studies.
 n Adoption of the recommendations will facilitate and improve 
worldwide communication of scientific advances in the field of 
interventional oncology.
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to produce stable findings in Delphi consensus projects (9). 
For each statement, panelists were given a free-text response 
option. Relevant items previously defined by Ahmed et  al 
(8) were presented, and panelists were asked whether the 
items could use adjustments. Items with strong consensus 
were locked and archived. Consensus was considered strong 
if all responses to a certain item were between 7 and 9, al-
lowing up to two outliers. Strong consensus for the remain-
ing single-answer multiple choice questions was defined as 
having reached at least 80% agreement among panelists. 
Data were analyzed anonymously.
The first-round answers were gathered and reported back to 
the panelists in the second round, where panelists rated only 
those items for which consensus had not been reached. Based 
on the first-round dispersal of scores (minimum, maximum, 
and median scores), each panelist was encouraged to reassess his 
or her initial judgments. Finally, for items remaining without 
consensus, a third round was organized. This in-person telecon-
ference, led by a representative of the coordinating committee 
(M.R.M.), involved members of the coordinating committee 
and evaluating committee. The remaining items were discussed, 
and a preliminary draft of the recommendations was composed 
for validation by all panelists.
Results
The coordinating committee drafted a list of 62 key opinion lead-
ers in the field of interventional oncology. Thirty-six of those 62 
experts (58%) participated in the first round. All panelists are 
board-certified interventional radiologists. The panelists had an 
average of 20.9 years of experience (standard deviation, 7.7 years) 
in the field of interventional radiology, 11.1 years of experience 
(standard deviation, 7.7 years) in clinical trials serving as princi-
pal investigator, and 17.7 years of experience (standard deviation, 
6.7 years) in clinical trials serving as collaborator. All panelists 
were familiar with oncologic outcome measures in their practice: 
78% (28 of 36 panelists) always use them and 22% (eight of 36 
panelists) use them occasionally. Additional detailed information 
regarding the panelists and their affiliated institutions is listed in 
Tables E1 and E2 (online). The experts rated a total of 62 items. A 
detailed comprehensive overview of the results, including all items 
and the level of agreement, is shown in Figure E1 (online).
Response rates were 58% (36 of 62 panelists), 56% (24 of 
43 panelists), and 54% (23 of 43 panelists) in rounds 1 (July 
to October 2019), 2 (November 2019 to January 2020), and 
3 (March 30, 2020), respectively. In round 1, consensus was 
reached on 27 of the 60 items (45%). The remaining 33 items 
were reiterated in the second round and two additional items, 
which emerged in the first round, were added. After two rounds, 
consensus was reached on 56 of the 62 items (90%). The re-
maining six items were discussed face-to-face in a videoconfer-
ence (round 3; March 30, 2020). No consensus was reached 
regarding the recommended validated classification system to 
register complications, adverse events, quality of life, and health 
economics–related issues, although the panelists did agree to rec-
ommend the following statement: To document complications, 
adverse events, quality of life, and health economics–related is-
sues, one should use and report the most recent version of a vali-
dated patient-reported outcome questionnaire.
In the first round, several panelists requested clarification re-
garding the use of the terms to document, to analyze, and to report. 
Accordingly, for future rounds the steering committee reached 
consensus regarding the following definitions: (a) to document 
means to collect and store patient-, procedure-, or tumor-related 
parameters in a centralized (preferably electronic, secure, and 
anonymized) study or registry database; (b) to analyze means 
to calculate, assess, and interpret congregated data derived from 
the documented patient-, procedure-, and tumor-related param-
eters; and (c) to report means to disclose the analyzed patient-, 
Flowchart of study design. The formal Delphi consensus method consisted of five 
steps: step 1, definition of problems, literature review, and appointing the experts’ 
committees (by the coordinating committee [CC]); step 2, development of defini-
tions and recommendations (by the coordinating committee); step 3, three-round 
rating process and evaluation of responses, including a final third round to reach 
consensus during a webinar (by the coordinating committee and evaluating com-
mittee [EC]); step 4, presentation of recommendations and manuscript to the evalu-
ating committee; and, step 5, creation of the final manuscript.
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procedure-, and tumor-related parameters in relation to the 
study outcomes with the intent to publish one’s findings.
The consensus items were translated into the following rec-
ommendations by the coordinating committee to which the 
evaluating committee anonymously agreed.
Recommendations
Addressing Outcomes per Patient, per Procedure, or per 
Tumor
When assessing time-to-event data in randomized controlled 
trials, single-arm prospective studies, and/or retrospective com-
parative and noncomparative series, the following definitions 
should be analyzed per patient and not on a per-tumor or per-
procedure basis: overall survival, disease-specific overall survival, 
disease-free survival, recurrence-free survival, progression-free 
survival, and distant progression-free survival (Table E3 [on-
line]). Parameters that address both procedure-related adverse 
effects and direct costs should be addressed per procedure. This 
includes short-terms complications, anesthesia techniques, hos-
pital-stay characteristics, and laboratory tests that, for example, 
assess organ function and the presence or absence of infectious 
complications. Technical success should be addressed per tumor 
and per procedure and not per patient. The term session can be 
used as a synonym for procedure. To assess the local efficacy of 
an ablative intervention, regardless of the oncologic outcome(s), 
one should address and report the following parameters per 
patient and per tumor: local tumor progression-free survival, 
time to local (tumor) progression, freedom from local or organ-
specific recurrence, primary and secondary or assisted technique 
efficacy, residual disease, local progression, recurrence rates, and 
local control. Multiple index tumors (eg, multiple colorectal 
metastases or multifocal hepatocellular carcinoma) within one 
unique patient cannot be regarded as independent as these tu-
mors are potentially correlated and hence study outcomes hy-
pothetically interlinked. When using standard survival estimates 
(Kaplan-Meier or cumulative incidence functions), in cases with 
multiple index tumors in one patient, the dependency of par-
tially correlated or clustered data is ignored and this potential 
limitation should be reported and stated in the discussion.
Starting and Ending Time Definitions
When assessing time-to-event data in randomized controlled tri-
als, patients who did not receive the allocated treatment should 
be included in the intention-to-treat analysis. According to 
the intention-to-treat analysis, the starting time should be the 
date of randomization. In trials where all patients, regardless of 
the eventual randomization arm, are treated with induction or 
neoadjuvant therapy, randomization should be performed after 
completion of the neoadjuvant therapy. In addition, adding a 
per-protocol analysis should be considered, including only pa-
tients who actually received the allocated treatment, especially if 
a potential bias due to exclusion of patients exists. According to 
the specific per-protocol analysis, when assessing time-to-event 
data in randomized controlled trials, the starting time should 
also be the date of randomization. In addition, it should be con-
sidered to add data regarding the time from the intervention, 
especially when the period between randomization and eventual 
intervention is long or heterogeneous or if a large number of 
crossovers and/or patient dropouts exist.
For single-arm prospective studies and for retrospective com-
parative and noncomparative series, the starting time should be 
the date of the first intervention even if the therapy may require 
completion procedures (eg, completion ablation for insufficient 
margins). In case of sequential procedures (eg, a preplanned two-
stage ablation followed by transarterial chemoembolization), the 
starting time should be the date of the first intervention.
When focusing on single-arm prospective series, where pa-
tients receive strict and homogeneous neoadjuvant or induction 
chemotherapy and/or radiation therapy regimens, one should 
document the time from (a) the date of detection of disease (di-
agnosis), (b) the date of the start of neoadjuvant or induction 
therapy, and (c) the date of the first interventional procedure.
If the risk of including a certain referral bias, lead-time bias, 
or immortality-time bias is present, then one should report time-
to-event data both from the date of diagnosis and from the date 
of the start of the intervention.
To assess mid- to long-term outcomes following a given in-
terventional procedure, one should document (a) the date of un-
equivocal presence of the event and (b) the date of an alternative 
event that excludes or alters the probability for a future event 
to occur (competing risk). During follow-up after a given in-
terventional procedure, one should separately document (a) the 
date of the last contact moment (eg, laboratory tests, phone calls, 
consultations) that reliably confirms or excludes the presence of 
a given event, (b) the date of the last cross-sectional imaging or 
surrogate test that reliably confirms or excludes the presence of 
the event, and (c) (non)physical contact moments (eg, nontu-
mor-specific laboratory tests, phone calls, consultations) that 
reliably exclude death, but not the presence or absence of disease.
Survival Time Definitions
If the patient’s likelihood of dying from causes other than the 
disease being studied is substantial (eg, as with elderly patients or 
those with early-stage disease with a good prognosis), one should 
document and report both overall survival and disease-specific 
overall survival. In the statistical analysis, death due to causes 
other than the disease being studied should be considered a com-
peting risk for the disease-specific survival analysis.
For early disease stages, when the intervention is likely cu-
rative (eg, ablation of small renal tumors), one should use re-
currence-free survival. For intermediate disease stages, when the 
intervention is considered potentially curative (eg, ablation of 
colorectal liver metastases), one should use disease-free survival. 
For advanced disease stages, when the intervention is considered 
palliative, one should use progression-free survival.
Time to progression is defined as the time between the start-
ing time and any disease recurrence (local, regional, or distant). 
Distant progression-free survival is defined as the time between 
the starting time and distant tumor progression, but not local 
or regional progression. Local tumor progression-free survival 
is defined as the time between the starting time and local tu-
mor progression per tumor treated (per-tumor analysis) or per 
patient treated (per-patient analysis). Time-to-local (tumor) 
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progression is defined as the time between the starting time 
and local tumor progression per tumor treated, resulting in a 
horizontally flipped survival curve (1 2 local tumor progres-
sion-free survival).
Death due to any cause without documented signs of local, 
regional, or distant disease progression should be considered a 
competing risk.
Time-to-Event Outcome Definitions and Data Censoring
To calculate the survival probability, one should use the Kaplan-
Meier survival estimate method, including the number of events 
and the numbers at risk at each evaluation time point. Cumula-
tive incidence function curves are preferred or should be added 
to the Kaplan-Meier estimates if the number of competing risks 
in a certain (sub)group is substantial, showing the cumulative 
failure rates over time due to a particular cause. With respect 
to data censoring, one should report the type of data censor-
ing (right-, left-, or interval-censored observations). The date of 
cross-sectional imaging or any other technique that unequivo-
cally demonstrates a certain event should be considered the date 
of the event (left-censored data). Both for interim and final anal-
yses, the date of assessment should be predefined either at a fixed 
point in time after inclusion of a certain number of individuals 
or after reaching a certain number of events. Any individuals 
remaining event-free and at risk should be right censored. Inter-
val-censored observations, where a virtual halftime date between 
two cross-sectional imaging examinations is considered as the 
actuarial date of the event, should be avoided.
Eligibility
In prospective randomized and nonrandomized studies, the 
number of eligible patients (who fulfill the inclusion criteria 
and who do not meet the criteria for exclusion) should be docu-
mented and reported, as well as the number of eligible patients 
who eventually do not participate. If possible, the reason for 
nonparticipation (eg, refusal or failure to meet the inclusion and 
exclusion criteria during work-up and/or during neoadjuvant or 
induction therapy) before formal recruitment (inclusion) should 
be documented and reported.
Recruited (included) patients who signed informed con-
sent are considered active study participants during the pre-
defined time they are “within the study.” Active study par-
ticipants who, for any reason (patient’s wish to end study 
participation or loss to follow-up), fail to continue participa-
tion in the period predefined as “within the study” should 
be considered study dropouts, regardless of whether they 
dropped out before or after randomization.
If active study participants refuse to undergo the allocated 
treatment arm, then the patient undoes their trial enroll-
ment. To eliminate any undesired impact on study-related 
outcomes, the investigators should formally end patients’ ac-
tive participation before they receive any alternative therapy. 
Patients who cross over from their allocated treatment arm 
to another study treatment arm, but who remain “within the 
study,” should be regarded as crossover patients. The number 
of patients who cross over to another treatment arm should 
always be minimized.
Technical Success, Technique Efficacy, Local Control, and 
Ablation Confirmation
Technical success addresses whether the tumor was treated ac-
cording to protocol and covered completely by the ablation 
zone, if possible by using ablation confirmation techniques (see 
explanation below). One should document and report the tech-
nical success rates. Technique efficacy refers to a prospectively 
defined point in time when complete ablation of macroscopic 
tumor was achieved, as evidenced by imaging follow-up or any 
alternative technique (ie, biopsy or serologic criteria). If a patient 
died due to any cause before that point in time, then the event 
should be analyzed and reported as a competing risk. Primary 
efficacy rate refers to the percentage of target tumors successfully 
eradicated following the initial ablation, whereas secondary or 
assisted technique efficacy rate refers to the percentage of target 
tumors eventually eradicated, including with repeat ablations, 
using the ablative method being studied. Local control is equiva-
lent to assisted technique efficacy, with the exception that repeat 
treatments using alternative methods (other ablative methods, 
radiation therapy, or surgical excision) are allowed. Residual 
unablated tumor refers to the presence of residual viable tumor 
at the ablative margin at initial follow-up imaging, whereas local 
tumor progression refers to reappearing viable tumor provided 
that at least one contrast-enhanced follow-up study did not re-
veal residual viable tumor at the ablative margin.
Ablation confirmation refers to postprocedural imaging, or 
any alternative technique, that is implemented with the intent 
to allow for additional overlapping (completion) procedures 
 either within the same procedure or in a complementary com-
pletion session in the days or weeks hereafter. For percutane-
ous ablations, one should attempt to document and report the 
minimum tumor-free margin. For CT-guided ablations, rigid 
or nonrigid image fusion and registration should be performed 
to confirm complete ablations, including circumferential safety 
margins of treated peri-ablational tissue (8,15,16). One should 
attempt to report the method of assessment of complete tumor 
coverage and safety margins (eg, image fusion software) as close 
to the time of ablation as possible, ideally immediately, or at least 
within 24 hours after ablation.
Complications, Adverse Events, Quality of Life, and Health 
Economics–related Outcomes
Complications, defined as any unexpected departure from a 
(post)procedural course, and adverse events, defined as any 
actual or potential injury related to a procedure, should be 
documented and reported, citing the most recent version of 
the used validated classification system so that they can be 
categorized consistently according to severity, time of occur-
rence (eg, intraprocedural, postprocedural, or late), and likeli-
hood of the event being related to the procedure. Although not 
meant to represent an exclusive list, the following classification 
systems are used to report complications and adverse events: 
(a) Common Terminology Criteria for Adverse Events standards, 
(b) Clavien-Dindo classification, (c) Society of Interventional Ra-
diology classification, and (d) Cardiovascular and Interventional 
Radiological Society of Europe Quality Assurance Document and 
Standards for Classification of Complications (17–20). In accor-
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dance with the previous standardization of terminology consensus 
document by Ahmed et al (8), pain should be reported using the 
most recent version of the Common Terminology Criteria for Ad-
verse Events of the National Cancer Institute.
Quality of life should be stratified according to disease stage 
and patient’s functional status. One should document and specifi-
cally cite the most recent version of the validated classification sys-
tem used. Quality of life should be assessed both before (baseline) 
and after treatment, regardless of disease progression. Although 
not meant to represent an exclusive list, the following standardized 
questionnaires have been issued for assessing the quality of life: 
(a) European Organization for Research and Treatment of Cancer, 
(b) Functional Assessment of Chronic Illness Therapy or Cancer 
Therapy, (c) World Health Organization Quality of Life scale 
(WHOQOL-BREF), (d) Health Utilities Index, (e) Short Form 
Health Surveys (SF-36, SF-12), (f) Nottingham Health Profile, 
(g) Quality of Well-Being Scale, and (h) Consumer Assessment 
of Healthcare Providers and Systems. Irrespective of the chosen 
method, one should always attempt to use general measures; can-
cer-, treatment-, and symptom-specific questionnaires; and non–
cancer-specific (satisfaction) questionnaires.
For health economics–related outcomes, both a cost-effective-
ness analysis and a comparative-effectiveness analysis are essential 
for defining the position of tumor ablation in relation to its alterna-
tives. Health economics–related outcomes should be documented 
and reported, specifically citing the most recent version of a vali-
dated classification system used. Although not meant to represent 
an exclusive list, standardized questionnaires that can be used in-
clude the generic EuroQoL Group (Rotterdam, the Netherlands) 
forms for the assessment of quality-adjusted life years (EQ-5D; 
EuroQol Group) and the Productivity and Disease Questionnaire, 
or PRODISQ, for the assessment of cost-effectiveness.
Discussion
Over the past 2 decades, image-guided thermal and nonthermal 
tumor ablation techniques have become indispensable therapeu-
tic options for a variety of cancer types. For certain smaller-size 
malignant tumors (eg, hepatocellular carcinoma, colorectal and 
other liver and lung metastases, renal cell carcinoma, prostate 
cancer, and neuroendocrine tumors), international guidelines 
have already adopted thermal ablation as a first-line treatment 
option (21–23). The continuing emergence of novel treatment 
options and growing demand for minimally invasive image-
guided tumor ablation techniques have raised the need for ev-
idence-based interventional oncology, and with that comes the 
need for clear documentation of oncologic outcome parameters.
The response rates in our study were 58%, 56%, and 54% 
in rounds 1, 2, and 3, respectively. After three rounds, consen-
sus was reached for all items but three (95%; 59 of 62 items). 
Consensus was not reached for the preferred validated classifi-
cation system to document, analyze, and report complications 
and adverse events, quality of life, and health economics–re-
lated issues. Nonetheless, the panelists unanimously agreed on 
the statement that “complications and adverse events, quality of 
life, and health economics–related issues should be documented 
and reported specifically citing the most recent version of the 
validated classification system used.” Review of the literature and 
discussions within the committees made it clear that outcome 
assessment in interventional oncology can be challenging. To 
date, neither a specific outcome nor a specific outcome measure 
is a widely accepted standard tool in interventional oncology. 
The disproportionate interest in the local effectiveness of a cer-
tain ablative technique and the complexity of correctly analyzing 
treatment methods that can be repeated and that can be used to 
treat  multiple index tumors in a single individual can explain 
this. However, it does not relieve treating physicians of their duty 
to provide hard and unequivocal evidence that our treatments 
 prolong survival, improve quality of life, or reduce costs.
These guidelines for the definition of time-to-event end points 
have been developed as an in-depth supplement to the more 
concise standardization of terminology and reporting criteria in 
image-guided tumor ablation published by Ahmed and colleagues 
(8). The participation of independent epidemiologists and mem-
bers of the Definition for the Assessment of Time-to-Event End 
Points in Cancer Trials initiative study group and the large number 
of international key opinion leaders from various institutions in 
the expert panel, as well as the relatively high response rates for 
all survey rounds, strengthen our methodology and indicate its 
importance. As stated by the Centre for Evidence-based Medicine, 
Delphi consensus studies are considered level 5 evidence (24). As 
an anonymous technique, it prevents expert participants from 
conforming to the opinion of others (25). Depending on the par-
ticipant selection tools, the number of rounds and what to do in 
which round, the specific cutoff values applied, and whether to 
discuss with the experts has led to several variants of the original 
Delphi method. The coordinating committee chose to use the 
well-documented three-step modified Delphi consensus method 
as proposed by Jones and Hunter (14), which is also used in the 
development of various national clinical guidelines.
One potential drawback of our study was the relative ho-
mogeneity of the academic and professional background of 
the panelists (all interventional radiologists). This may impair 
the generalizability and validity of the recommendations made 
herein. Nonetheless, image-guided tumor ablation is most often 
performed by interventional radiologists, and the responsibility 
to attend multidisciplinary tumor boards, to have a thorough 
understanding of the guidelines and available evidence, to es-
tablish periprocedural care, and to provide robust evidence for 
new oncologic interventions has previously been emphasized 
by many, thus minimizing this limitation. General limitations 
of the Delphi consensus method are the lack of guidance and 
agreed standards on how to select participants and the fact that 
it is time-consuming and laborious for participants, which ex-
plains why it is vulnerable to dropouts. Participants might also 
drop out due to the long temporal commitment, distraction be-
tween rounds, or disappointment with the process.
This study provides a framework of key opinion leader 
recommendations regarding patient-, procedure-, and tumor-
related definitions, starting and ending time definitions, sur-
vival time definitions, time-to-event end points, and patient-
reported outcome measures. Clear definitions will provide the 
necessary foundation for scientific reproducibility between 
studies as they will ensure an objective and reliable interpreta-
tion of results, allow for accurate comparison of outcomes, and 
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avoid misinterpretations. We encourage all of our colleagues 
to adopt the recommendations outlined in this proposal to fa-
cilitate worldwide communication of scientific advances in the 
field of interventional oncology.
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